Neuromuscular Diseases Care in the Era of COVID-19
Open Access
- 26 November 2020
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 11, 588929
- https://doi.org/10.3389/fneur.2020.588929
Abstract
The COVID-19 pandemic has pushed health systems to their limit and forced readjustment of standards of care for different pathologies. Management of neuromuscular diseases becomes a challenge since most of them are chronic, disabling, progressive, and/or require immunosuppressive drugs. There are three main aspects of COVID-19 that affect neuromuscular diseases care. The first one relates to how SARS-CoV2 directly affects different neuromuscular pathologies. Respiratory weakness, as seen in myasthenia gravis, amyotrophic lateral sclerosis, and myopathies, and the use of immunomodulatory drugs (Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy) make this group of patients potentially more vulnerable. Secondly, safety measures also affect proper care, limiting care continuity, and physical rehabilitation (one of the essential aspects of myopathies treatment). Telemedicine can partially solve the problem allowing for a continuum of close care, avoiding unnecessary visits, and even guaranteeing the attention of professionals from tertiary care centers. However, one of the crucial steps in neuromuscular diseases is diagnosis, and in most scenarios, more than one face-to-face visit is needed. Lastly, the global COVID-19 situation will also have an economic impact on patients and their families. This situation is of particular concern given that neuromuscular diseases already present difficulties due to the scarcity of resources in terms of public healthcare and research.This publication has 46 references indexed in Scilit:
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort studyThe Lancet, 2020
- Serious infections in patients with myasthenia gravis: population‐based cohort studyEuropean Journal of Neurology, 2020
- Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendationsRMD Open, 2019
- Adjusted cost analysis of video televisits for the care of people with amyotrophic lateral sclerosisMuscle & Nerve, 2019
- Myasthenia gravis and infectious diseaseZeitschrift für Neurologie, 2018
- Report by the Spanish Foundation for the Brain on the social impact of amyotrophic lateral sclerosis and other neuromuscular disordersNeurología (English Edition), 2018
- Comparative Rates of Serious Infections Among Patients With Systemic Lupus Erythematosus Receiving Immunosuppressive MedicationsArthritis & Rheumatology, 2016
- Effect of therapeutic plasma exchange on immunoglobulins in myasthenia gravisAutoimmunity, 2016
- Disease burden of spinal muscular atrophy in GermanyOrphanet Journal of Rare Diseases, 2016
- Scrutinizing enrollment in ALS clinical trials: Room for improvement?Amyotrophic Lateral Sclerosis, 2008